SLC38A2 and neoplasm: The overexpression of SLC38A2 enhances the nutritional tug-of-war between tumor cells and immune cells, inhibiting the activity of effector T cells (CD8+ T cells) while increasing the abundance of tumor-promoting Th2 cells.